| 1. |
|
|
| 2. |
- Schmitt, F. C., et al.
(author)
-
Standardisierter Computer-basiert- o rganisierter Report des EEG (SCORE) - Eine strukturierende Form der EEG-Befundung
- 2018
-
In: Klinische Neurophysiologie. - : Georg Thieme Verlag KG. - 1434-0275 .- 1439-4081. ; 49:2, s. 1-18
-
Journal article (peer-reviewed)abstract
- A taskforce formed in 2013 by the International Federation of Clinical Neurophysiology developed an EEG terminology with international consensus. In the following, the result - the second version of Standardized Computer-based Organized Reporting of EEG (SCORE) will be summarised. The terminology was tested in clinical practice using a software package (SCORE-EEG) applied to over 12,000 EEGs. The selection of terms is context-dependent: the initial selection determines which further options are available. A report is automatically generated and individual features are fed into a database. SCORE contains specialised modules for reporting on epileptic seizures, as well as for characteristic neonatal and intensive care EEG features. SCORE is a useful tool not only for outpatient, clinical and research settings, but also for quality control, data sharing and education.
|
|
| 3. |
- Düzel, Emrah, et al.
(author)
-
Innovation in der Diagnostik – mobile Technologien
- 2019
-
In: Nervenarzt. - : Springer Science and Business Media LLC. - 0028-2804. ; 90:9, s. 914-920
-
Research review (peer-reviewed)abstract
- Background: Progressive cognitive deficits are the main clinical symptom of Alzheimer’s disease; however, the precise recording of cognitive deficits and assessment of their progression pose major problems in patient care and early interventions. Objective: Which problems for care and early intervention result from the current practice of cognitive assessment of patients with memory problems and which opportunities arise from the use of mobile apps? Material and methods: Evaluation of current care structures, discussion of basic work, expert recommendations and current developments. Results: The current practice of the pencil and paper-based diagnostics of cognitive deficits, which is temporally and spatially bound to a clinical environment, constrains the feasibility, validity and reliability of cognitive assessment and the quantification of progression. This limits the meaningful use of further diagnostic measures, such as magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) analyses. Recent progress in mobile app-based technologies, illustrated here with the example of the neotiv app, can help to overcome these problems. Conclusion: Mobile app-based technologies can help to improve the cognitive assessment of patients with the main symptom of memory complaints. They can reduce overuse and underuse of diagnostic and therapeutic pathways and enable a targeted and meaningful use of advanced diagnostics. In addition, they can structure risk-modifying preventive measures, identify iatrogenic impairment of cognition and in this respect also strengthen patient competence.
|
|
| 4. |
- Honig, H., et al.
(author)
-
Wirkung von Apomorphin auf nicht motorische Symptome bei Morbus Parkinson
- 2011
-
In: Aktuelle Neurologie. - : Georg Thieme Verlag KG. - 0302-4350 .- 1438-9428. ; 38:Suppl. 1, s. 34-38
-
Research review (peer-reviewed)abstract
- In Parkinson's disease non-motor symptoms can appear even before the motor symptoms. Additionally to motor fluctuations and dyskinesias, the non-motor symptoms constitute one of the main problems when treating Parkinson's disease. They are also of high relevance for the quality of life. There are indications that a continuous dopaminergic stimulation can improve symptoms such as depression, sleep as well as autonomic disturbances. Treatment with apomorphine infusion subcutaneously or Duodopa (L-dopa/carbidopa) intraduodenally with portable pump systems are well-established regarding management of motor fluctuations and dyskinesias. Regarding effects on non-motor symptoms there are so far only a few studies with limited number of cases available.
|
|
| 5. |
- Jost, W. H., et al.
(author)
-
King’s Parkinson’s Disease Pain Scale : Interkulturelle Adaption in deutscher Sprache
- 2018
-
In: Nervenarzt. - : Springer Science and Business Media LLC. - 0028-2804. ; 89:2, s. 178-183
-
Journal article (peer-reviewed)abstract
- Background: Pain is a frequent symptom of idiopathic Parkinson’s disease and has a substantial impact on quality of life. The King’s Parkinson’s disease pain scale (KPPS) has become internationally established and is an English-language, standardized, reliable and valid scale for evaluation of pain in idiopathic Parkinson’s disease. This article presents a validated version in German. Method: The German translation was adapted interculturally and developed using an internationally recognized procedure in consultation with the authors of the original publication. The primary text was first translated by two bilingual neuroscientists independently of one another. Thereafter, the two versions were collated to generate a consensus version, which was accepted by the translators and preliminarily trialled with 10 patients. Hereafter, the German version was re-translated back into English by two other neurologists, again independently of one another, and a final consensus was agreed on using these versions. This English version was then compared with the original text by all of the translators, a process which entailed as many linguistic modifications to the German version as the translators considered necessary to generate a linguistically acceptable German version that was as similar as possible to the original English version. After this test text had been subsequently approved by the authors, the German text was applied to 50 patients in two hospitals, and reviewed as to its practicability and comprehensibility. Results: This work led to the successful creation of an inter-culturally adapted and linguistically validated German version of the KPPS. Discussion: The German version presented here is a useful scare for recording and quantifying pain in empirical studies, as well as in clinical practice.
|
|
| 6. |
- Norrving, Bo
(author)
-
Lakuäre Infarkte
- 2003
-
In: Therapeutische Umschau. - : Hogrefe Publishing Group. - 0040-5930 .- 1664-2864. ; 60:9, s. 535-540
-
Journal article (peer-reviewed)abstract
- Lacunar infarcts, small deep infarcts resulting from occlusion of a penetrating artery, account for about a quarter of all ischemic strokes. The view of lacunar infarcts as a benign and rather innocent vascular lesion has been modified during the last years. Although the prognosis is more favourable than other subtypes during the first years, probably due to the small lesion size, in a longer perspective there is an excess risk of death, continual occurrence of recurrent stroke, and development of cognitive dysfunction. The risk of recurrent stroke is similar to most other types of stroke, and patients are at increased risk to develop cognitive decline and dementia. Increasing age, vascular risk factors, and high nocturnal blood pressure have significant prognostic implications for almost all outcomes. Lacunar infarcts and ischemic white-matter disease, the two main types of cerebral small-vessel disease, frequently co-exist and have synergistic effects on prognosis and risk of cognitive decline. Antiplatelet therapy and risk factor modification are the cornerstones in secondary prevention after a lacunar infarct.
|
|
| 7. |
- Odin, Per, et al.
(author)
-
Apomorphininjektionstherapie bei Morbus Parkinson
- 2011
-
In: Aktuelle Neurologie. - : Georg Thieme Verlag KG. - 0302-4350 .- 1438-9428. ; 38:Suppl. 1, s. 11-16
-
Research review (peer-reviewed)abstract
- Apomorphine as subcutaneous injections offers a valuable and effective treatment alternative for Parkinson patients with oral medication-resistant "off' phases. Its efficacy is stable during long-term therapy, with no signs of patient tolerance. Adverse events are usually mild. The best results are obtained with relatively young, active, and cognitively intact patients. Intermittent s.c. apomorphine therapy can improve the patients' possibilities to continue to work and to live a normal social life, by offering increased freedom and self-confidence through a reliable, quick rescue from the disabling medication-resistant off phases.
|
|
| 8. |
- Sixel-Doering, F., et al.
(author)
-
Apomorphin zur subkutanen Dauerinfusion bei fortgeschrittenem Morbus Parkinson: Effektivität, Verträglichkeit und Patientenzufriedenheit im Langzeitverlauf
- 2011
-
In: Aktuelle Neurologie. - : Georg Thieme Verlag KG. - 0302-4350 .- 1438-9428. ; 38:Suppl. 1, s. 27-33
-
Research review (peer-reviewed)abstract
- Subcutaneous continuous infusion of apomorphine has been shown to effectively reduce off-time and dyskinesias in Parkinson's disease (PD). In this multicentre observational cohort study we investigated motor effectivity, tolerability and patient satisfaction with subcutaneous apomorphine infusion therapy over a follow-up period of 2 years. 62 PD patients were included (34 women, 28 men; median age 67.7 years). 33 of 62 patients (53%) continued therapy throughout the study period, showing a 79% reduction of daily off-time at the end of the observation period as compared to baseline. A third of these patients reported a lasting, subjective improvement of dyskinesias. At the end of the 2 years 75.8% of patients for final evaluation rated their satisfaction with subcutaneous apomorphine infusions as good". Altogether 29 patients (47%) stopped apomorphine infusions in the course of the study, most of them during the 3(rd) and 12(th) month of therapy. 8 cases stated adverse effects and 4 cases insufficient efficacy as reasons for discontinuation of therapy. 4 patients died during the observation period, 3 patients as a result of concomitant disease most likely not related to apomorphine, and 1 patient due to insufficiently treated medication-induced paranoid psychosis probably related to apomorphine. 6 patients were lost to follow-up. Conclusion Apomorphine therapy was effective with patient satisfaction rated as good in 53% of patients over a period of 2 years. Besides adverse events, low acceptance of long-term pump therapy as well as disease progression may be possible reasons for stopping apomorphine infusions. Physicians caring for PD patients with apomorphine therapy should be trained in the use of the substance to ensure safety and best possible therapy management.
|
|
| 9. |
- Storch, A., et al.
(author)
-
Non-motor Symptoms Questionnaire and Scale for Parkinson's disease
- 2010
-
In: Nervenarzt. - : Springer Science and Business Media LLC. - 0028-2804. ; 81:8, s. 980-985
-
Journal article (peer-reviewed)abstract
- Idiopathic Parkinson's disease (PD) is a multisytem degenerative disorder. In addition to motor symptoms such as akinesia, rigidity and tremor, various non-motor symptoms occur, which are still insufficiently diagnosed. Moreover, the frequently used scales and scores do not adequately detect these non-motor symptoms. The Non-motor Symptoms Questionnaire (NMSQuest) is an established self-completed patient questionnaire with 30 qualitative questions covering all important non-motor symptoms of PD. The Non-motor Symptoms Scale (NMSScale) is a grade rating scale for estimating the frequency and severity of non-motor symptoms in PD. Since there are only original English versions of both questionnaires available, self-translated versions were frequently used or the questionnaires were not used at all in native German patients. We used international guidelines for cross-cultural adaptation of questionnaires to provide standard versions of both non-motor symptoms questionnaires in the German language.
|
|
